What is the appropriate assessment and management plan for a 62‑year‑old woman presenting with new‑onset atrial fibrillation with rapid ventricular response, intermittent chest pain, dyspnea on exertion, orthopnea, and no prior history of hypertension, diabetes, coronary artery disease, or heart failure?

Assessment and Management of New-Onset Atrial Fibrillation with Rapid Ventricular Response

This patient requires immediate rate control with intravenous beta-blockers (metoprolol or esmolol), urgent workup for tachycardia-induced cardiomyopathy, and initiation of anticoagulation based on stroke risk stratification.

Immediate Assessment Priorities

1. Hemodynamic Stability and Underlying Etiology

This patient is hemodynamically stable (BP 110/85, speaking in phrases, no acute pulmonary edema), which directs management toward rate control rather than emergent cardioversion 1, 2. However, the constellation of symptoms—4 months of progressive dyspnea on exertion, orthopnea, and chest pain—strongly suggests new-onset heart failure potentially caused by the rapid AF (tachycardia-induced cardiomyopathy).

Critical distinction: The 2014 AHA/ACC/HRS guidelines emphasize that AF with rapid ventricular response is one of the few potentially reversible causes of heart failure 2. A patient presenting with newly detected heart failure in the presence of AF with RVR should be presumed to have rate-related cardiomyopathy until proven otherwise 2.

2. Key Diagnostic Workup

Immediate investigations needed:

• Transthoracic echocardiogram (urgent): Assess left ventricular ejection fraction, valvular disease, left atrial size, and exclude structural heart disease 3, 4
• Troponin: Given chest pain and tachycardia, rule out acute coronary syndrome or myocardial ischemia 5
• Thyroid function tests (TSH): Exclude hyperthyroidism as precipitant 3, 4
• Complete blood count, electrolytes, creatinine: Baseline for medication dosing and identify reversible causes 4
• Chest X-ray: Evaluate for pulmonary congestion, cardiomegaly

The history of DVT requiring IVC filter placement is notable and may indicate underlying hypercoagulability or prior thrombotic risk.

Rate Control Strategy

Acute Rate Control (First-Line)

Intravenous beta-blockers are the preferred initial agents 2, 1, 2:

• Metoprolol 2.5-5 mg IV bolus over 2 minutes, repeat every 5-10 minutes up to 15 mg total
• OR Esmolol 500 mcg/kg loading dose over 1 minute, then 50-200 mcg/kg/min infusion

Rationale: Beta-blockers are preferred because they have favorable effects on morbidity and mortality in patients with systolic heart failure 2. Exercise caution if overt heart failure with reduced ejection fraction is present, but this patient shows compensated status currently 2.

Alternative if beta-blockers contraindicated or insufficient:

• Diltiazem 0.25 mg/kg IV (typically 15-25 mg) over 2 minutes, followed by 5-15 mg/hr infusion
• Digoxin 0.25 mg IV or amiodarone 150 mg IV if heart failure with reduced EF is confirmed 1, 2, 1

Target heart rate: <110 bpm at rest initially (lenient rate control acceptable) 2

Transition to Oral Rate Control

Once acute rate controlled:

• Metoprolol 25-50 mg PO twice daily (titrate to effect)
• OR Diltiazem extended-release 120-360 mg daily
• Consider adding digoxin 0.125-0.25 mg daily if monotherapy insufficient, especially if heart failure confirmed 2, 1

Important caveat: If echocardiogram reveals reduced ejection fraction (<40%), avoid or use diltiazem with extreme caution due to negative inotropic effects 2. Beta-blockers remain preferred in this scenario.

Rhythm Control Consideration

Given the suspected tachycardia-induced cardiomyopathy, two strategies are reasonable 2:

1. Rate control first: Optimize rate control, reassess LV function in 4-6 weeks. If EF improves, confirms rate-related cardiomyopathy.

2. Rhythm control approach: Initiate amiodarone 200 mg three times daily for 1 week, then 200 mg twice daily for 1 week, then 200 mg daily maintenance, with planned cardioversion in 3-4 weeks after adequate anticoagulation 2.

Amiodarone has the dual advantage of providing both rate control and being the most effective antiarrhythmic with low proarrhythmic risk 2. This is particularly useful when tachycardia-induced cardiomyopathy is suspected 2, 6.

Anticoagulation for Stroke Prevention

Stroke Risk Stratification

Calculate CHA₂DS₂-VASc score 7, 8:

• Congestive heart failure: 0 (pending echo, but symptoms suggest possible 1 point)
• Hypertension: 0 (BP 110/85, no documented history)
• Age ≥75: 0
• Diabetes: 0
• Stroke/TIA/thromboembolism: 0 (but DVT history noted—see below)
• Vascular disease: 0 (no documented CAD)
• Age 65-74: 1 point (age 62)
• Sc (Sex category—female): 1 point

Preliminary score: 2 points (potentially 3 if heart failure confirmed on echo)

Anticoagulation Recommendation

Oral anticoagulation is indicated with CHA₂DS₂-VASc ≥2 7, 8:

Direct oral anticoagulants (DOACs) are first-line 7, 8:

• Apixaban 5 mg twice daily (preferred for safety profile)
• OR Rivaroxaban 20 mg daily with evening meal
• OR Dabigatran 150 mg twice daily
• OR Edoxaban 60 mg daily

Timing considerations 9:

• Duration of AF unknown (symptoms for 4 months suggest persistent AF)
• Do NOT cardiovert without 3 weeks of therapeutic anticoagulation OR transesophageal echocardiogram to exclude left atrial appendage thrombus 9
• If cardioversion planned: Anticoagulate for ≥3 weeks before and ≥4 weeks after cardioversion 9
• Long-term anticoagulation: Continue indefinitely given CHA₂DS₂-VASc ≥2, regardless of whether sinus rhythm is restored 9

Special consideration: The patient's history of DVT requiring IVC filter suggests prior thrombotic risk, which further supports aggressive anticoagulation.

Disposition and Follow-Up

Admission Criteria

This patient should be admitted for:

• Suspected new-onset heart failure requiring workup
• Initiation and monitoring of rate control medications
• Echocardiogram and further evaluation for tachycardia-induced cardiomyopathy
• Anticoagulation initiation with monitoring

Follow-Up Plan

• Cardiology consultation within 1-2 weeks
• Repeat echocardiogram in 4-6 weeks after rate control optimization to assess for improvement in LV function 2
• Exercise tolerance testing to assess rate control adequacy during activity 1, 2
• Consider rhythm control strategy (cardioversion or catheter ablation) if symptoms persist despite rate control or if tachycardia-induced cardiomyopathy confirmed 2, 6

Common Pitfalls to Avoid

1. Do not use IV calcium channel blockers or beta-blockers if decompensated heart failure present 2—this patient appears compensated, but reassess continuously

2. Do not cardiovert without adequate anticoagulation when AF duration >48 hours or unknown 9

3. Do not assume rate control alone is sufficient—this patient likely has tachycardia-induced cardiomyopathy requiring rhythm control consideration 2

4. Do not discontinue anticoagulation even if sinus rhythm restored, given CHA₂DS₂-VASc ≥2 9

5. Do not use digoxin as monotherapy for acute rate control—it is ineffective for controlling rate during exercise and has slow onset 1